TG Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

TG Therapeutics

06/08/2024 14:32

* TG Therapeutics Inc  TGTX.OQ  reported quarterly adjusted
earnings of 4 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -34 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 5 cents per
share. Wall Street expected results to range from -9 cents to -2
cents per share.
    * Revenue rose 357% to $73.47 million from a year ago;
analysts
expected $65.89 million. 
    * TG Therapeutics Inc's reported EPS for the quarter was 4
cents​.
    * The company reported quarterly net income of $6.88
million.
    * TG Therapeutics Inc shares had fallen by 3.3% this
quarter and
gained 0.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for TG Therapeutics
Inc is $34.50 
This summary was machine generated from LSEG data August 6 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.05          0.04           Beat
 Mar. 31 2024      -0.04          -0.07          Missed
 Dec. 31 2023      -0.10          -0.10          Met
 Sep. 30 2023      0.12           0.73           Beat